Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
Author:
Affiliation:
1. “Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
Publisher
Informa UK Limited
Subject
Hematology
Link
https://www.tandfonline.com/doi/pdf/10.1080/17474086.2018.1456331
Reference72 articles.
1. Improved survival in multiple myeloma and the impact of novel therapies
2. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
3. CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
4. CD38 and chronic lymphocytic leukemia: a decade later
5. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments;Current Oncology;2023-08-27
2. Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging;Biomedicines;2023-07-24
3. SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis;Journal of Clinical Investigation;2023-03-15
4. Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update;American Journal of Hematology;2021-11-10
5. Library-based lead compound discovery for CS-1 protein in multiple myeloma: homology modelling, molecular dynamic simulations, virtual screening and molecular docking;Molecular Simulation;2021-08-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3